Melinta Therapeutics, Inc. (MLNT) SEC Filing 8-K Material Event for the period ending Thursday, October 18, 2018

Melinta Therapeutics, Inc.

CIK: 1838000 Ticker: MLNT

View differences made from one to another to evaluate Melinta Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Melinta Therapeutics, Inc..


Assess how Melinta Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Melinta Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Melinta Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: MLNT
CIK: 1461993
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-306463
Submitted to the SEC: Wed Oct 24 2018 4:59:59 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Thursday, October 18, 2018
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: